Overview
Scynexis Q3 2025 net loss widens to $8.6 mln
Company receives $24.8 mln one-time payment from GSK, extending cash runway over two years
Outlook
Scynexis expects up to $146 mln in annual net sales milestones from BREXAFEMME relaunch
Scynexis's cash runway extends over two years, supporting SCY-247 development
Result Drivers
GSK PAYMENT - Scynexis received a one-time payment of $24.8 mln from GSK, resolving a disagreement over the Phase 3 MARIO study
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Product Revenue | $334,000 | ||
Q3 Net Income | -$8.59 mln | ||
Q3 Basic EPS | -$0.17 | ||
Q3 Operating Expenses | $8.74 mln | ||
Q3 Pretax Profit | -$8.59 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for SCYNEXIS Inc is $4.00, about 84.2% above its November 4 closing price of $0.63
Press Release: ID:nGNX84CtD5
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)